ஈயந் க்ராஸ்பி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஈயந் க்ராஸ்பி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஈயந் க்ராஸ்பி Today - Breaking & Trending Today

Investegate |Sequana Medical NV Announcements | Sequana Medical NV: Sequana Medical announces positive results from second interim analysis of North American pivotal alfapump® study (POSEIDON)

Sequana Medical NV
(Euronext Brussels: SEQUA, the Company or Sequana Medical ), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces positive results from the second interim analysis of POSEIDON, the North American pivotal study of the
alfapump for the treatment of recurrent or refractory ascites due to liver cirrhosis. These interim data from 26 patients in the Roll-In Cohort are in line with the previous interim data
ii, including positive outcomes against all primary endpoints of the study and a rapid and persistent clinically important improvement in quality of life measures. ....

United States , Cian Crosbie , Florence Wong , Guillaume Van Renterghem , University Of Toronto , Company Or Sequana , Clinical Events Committee , Sequana Medical , North American , Roll In Cohortreconfirm , Euronext Brussels , Roll In Cohort , Pivotal Cohort , Premarket Approval , Chief Executive Officer , Toronto General Hospital , Principal Investigator , Minimal Clinically Important Difference , Clinical Events , Non Alcoholic Steatohepatitis , Direct Sodium Removal , ஒன்றுபட்டது மாநிலங்களில் , ஈயந் க்ராஸ்பி , புளோரன்ஸ் வோங் , பல்கலைக்கழகம் ஆஃப் டொராண்டோ , மருத்துவ நிகழ்வுகள் குழு ,

Sequana Medical Announces Positive Results From Second

GHENT, Belgium, July 01, 2021 (GLOBE NEWSWIRE)
Sequana Medical NV (Euronext Brussels: SEQUA, the Company or Sequana Medical ), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces positive results from the second interim analysis of POSEIDON, the North American pivotal study of the
alfapump for the treatment of recurrent or refractory ascites due to liver cirrhosis. These interim data from 26 patients in the Roll-In Cohort are in line with the previous interim data
ii, including positive outcomes against all primary endpoints of the study and a rapid and persistent clinically important improvement in quality of life measures. ....

United States , Cian Crosbie , Florence Wong , University Of Toronto , Company Or Sequana , Roll In Cohort , Euronext Brussels , North American , Pivotal Cohort , Premarket Approval , Chief Executive Officer , Sequana Medical , Toronto General Hospital , Principal Investigator , ஒன்றுபட்டது மாநிலங்களில் , ஈயந் க்ராஸ்பி , புளோரன்ஸ் வோங் , பல்கலைக்கழகம் ஆஃப் டொராண்டோ , ரோல் இல் கூட்டுறவு , வடக்கு அமெரிக்கன் , முக்கிய கூட்டுறவு , தலைமை நிர்வாகி அதிகாரி , டொராண்டோ ஜநரல் மருத்துவமனை , ப்ரிந்ஸிபல் புலனாய்வாளர் ,

Sequana Medical NV: Sequana Medical announces positive results from second interim analysis of North American pivotal alfapump study (POSEIDON)

Sequana Medical NV: Sequana Medical announces positive results from second interim analysis of North American pivotal alfapump study (POSEIDON)
i
All patients experienced
Safety
Primary endpoint read-out
Sequana Medical NV
(Euronext Brussels: SEQUA, the Company or Sequana Medical ), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces positive results from the second interim analysis of POSEIDON, the North American pivotal study of the
alfapump for the treatment of recurrent or refractory ascites due to liver cirrhosis. These interim data from 26 patients in the Roll-In Cohort are in line with the previous interim data ....

United States , Cian Crosbie , Florence Wong , Guillaume Van Renterghem , University Of Toronto , Company Or Sequana , Clinical Events Committee , Roll In Cohortreconfirm , Euronext Brussels , North American , Roll In Cohort , Pivotal Cohort , Premarket Approval , Chief Executive Officer , Sequana Medical , Toronto General Hospital , Principal Investigator , Minimal Clinically Important Difference , Non Alcoholic Steatohepatitis , Direct Sodium Removal , ஒன்றுபட்டது மாநிலங்களில் , ஈயந் க்ராஸ்பி , புளோரன்ஸ் வோங் , பல்கலைக்கழகம் ஆஃப் டொராண்டோ , மருத்துவ நிகழ்வுகள் குழு , வடக்கு அமெரிக்கன் ,

Sequana Medical NV: Sequana Medical announces first patient enrolled in SAHARA DESERT

alfapump DSR study in Heart Failure patients with persistent congestion Ghent, BELGIUM - 1 June 2021 - Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the treatment of diuretic-resistant ....

United States , Republic Of Georgia , Cian Crosbie , Guillaume Van Renterghem , Heart Failure , Euronext Brussels , Chief Medical Officerat Sequana , Direct Sodium Removal , Chief Executive Officer , Sequana Medical , North American , ஒன்றுபட்டது மாநிலங்களில் , குடியரசு ஆஃப் ஜார்ஜியா , ஈயந் க்ராஸ்பி , இதயம் தோல்வி , நேரடி சோடியம் அகற்றுதல் , தலைமை நிர்வாகி அதிகாரி , வடக்கு அமெரிக்கன் ,

Sequana Medical NV: Sequana Medical announces strong top-line results from RED DESERT alfapump DSR study and expansion of DSR development programme

Sequana Medical NV: Sequana Medical announces strong top-line results from RED DESERT alfapump DSR study and expansion of DSR development programme
-
s
improvement in diuretic
Conference call with
Euronext Brussels: SEQUA
), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces positive top-line results from the RED DESERT study with repeated dose
alfapump DSR
SAHARA DESERT, the study of the
alfapump DSR in diuretic-resistant heart failure patients with residual congestion is on track to start before the end of this quarter, with interim results expected before year-end and top-line results expected in H2 2022. ....

United States , Region Flamande , Jeffrey Testani , Cian Crosbie , Chris Mcintyre , Guillaume Van Renterghem , Professor At Yale University , Lawson Health Research Institute , Data Monitoring Committee , Euronext Brussels , Direct Sodium Removal , Sequana Medical , Chief Executive Officer , Principal Investigator , Interventional Cardiologist , Onze Lieve Vrouw Hospital , Associate Professor , Yale University , Heart Failure Scientific Advisor , North American , ஒன்றுபட்டது மாநிலங்களில் , ஈயந் க்ராஸ்பி , கிறிஸ் முசந்த்ிரே , ப்ரொஃபெஸர் இல் யேல் பல்கலைக்கழகம் , லாசன் ஆரோக்கியம் ஆராய்ச்சி நிறுவனம் , தகவல்கள் கண்காணிப்பு குழு ,